Drug Trial Radar · NCT06420089
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Oct 4, 2024
Primary completion
Sep 24, 2026
Study completion Sep 24, 2026
Sponsor
- Lead sponsor
- Vittoria BiotherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- University of Pennsylvania
- First posted
- May 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label phase I study to determine the safety and recommended phase 2 dose (RP2D) of Senza5 CART5 cells in patients with relapsed or refractory CD5 positive nodal T cell NHL. RP2D will be based on the safety, tolerability, pharmacokinetics, and preliminary efficacy of Senza5 CART5 cells. This trial will evaluate up to 5 dose levels using the Bayesian Optimal Interval (BOIN) design enrolling 3 patients in each cohort to assess safety and achieve therapeutic levels so that the RP2D of Senza5 CART5 cells given as a single IV infusion can be determined.
Conditions
- T Cell Non-Hodgkin Lymphoma
Interventions
Senza5 CART5Drug
The Senza5 CART5 drug product consists of a dual population of engineered autologous T cells: CD5 knockout (KO)cells and CD5KO-CART5 cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the recommended phase 2 dose (RP2D) of Senza5 CART5 cellsTime frame: 12 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Columbia University Irving Medical Center
New York, New York
University of Pennsylvania - Abramson Caner Center
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.